Evidence map›Paper›PMID 41674662›Full record

ArticleGenes & diseases2026

Dual-mode aptamer-driven biosensing platform for ultrasensitive and mutation-resilient detection of the SARS-CoV-2 nucleocapsid protein.

Shu Zhou, Yuxi Xu, Huan Liao, Hailong Ou, Dan Qi, Yatao Wu, Yunyi Liu, Juan Li, Jiaxuan Li, Bi Shi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shu ZhouState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.
Yuxi XuState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.
Huan LiaoState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.
Hailong OuState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.
Dan QiDepartment of Neurosurgery, Neuroscience Institute, Baylor Scott & White Health, Temple, TX 76508, USA.
Yatao WuState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.
Yunyi LiuState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.
Juan LiState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.
Jiaxuan LiState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.
Bi ShiState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.
Fei ZhuState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.
Siran ZhangState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.
Jason H HuangDepartment of Neurosurgery, Neuroscience Institute, Baylor Scott & White Health, Temple, TX 76508, USA.
Erxi WuDepartment of Neurosurgery, Neuroscience Institute, Baylor Scott & White Health, Temple, TX 76508, USA.
Xiaoxiao HuState Key Laboratory of Chemo and Biosensing, College of Biology, Molecular Science and Biomedicine Laboratory, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan University, Changsha, Hunan 410082, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a significant global health threat because of its rapid evolution and high mutation rate, which limits the performance of existing molecular diagnostics. This study presents a dual-mode, aptamer-based detection platform that combines high sensitivity with mutation resilience. Using a computer-assisted X-aptamer Systematic Evolution of Ligands by EXponential enrichment (SELEX) approach, we identified NP14, a high-affinity, dual-target DNA aptamer that specifically binds to the SARS-CoV-2 nucleocapsid (N) protein at its N-terminal domain. Analyses via molecular docking, aptamer truncation, and targeted mutagenesis revealed that NP14 interacted with both SARS-CoV-2 and SARS-CoV N proteins and identified key nucleotides C24 and G27 of the P1 region and structural determinants critical for its high-affinity binding. Building on this discovery, we engineered a dual-mode biosensing system by integrating NP14 into a multicolor dynamic light scattering-enhanced enzyme-linked aptamer-antibody assay (MD ELAAA). MD ELAAA synergistically combines two complementary detection strategies: i) non-aggregative plasmonic colorimetry for visual signal detection and ii) dynamic light scattering for ultrasensitive quantitative analysis, in which Au/Ag nanomaterials are used to amplify optical and scattering signals. This system achieves a sensitivity of 0.43 TCID

Indexed as

AptamerAptamer-antibody sandwich assayDynamic light scatteringMutationSARS-CoV-2 N protein

Identifiers

PMID41674662
PMCPMC12886537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.